Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | PNP | P00491 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KDM4A | O75164 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | IDH1 | O75874 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.31 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.31 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.31 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL649075 | 0.73 | ALDH1A1 (0.46) | TAAR1LTA4HMEN1ALDH1A1KMT2A | |
| Immethridine SCHEMBL845141 | 0.72 | HRH4 (0.44) | LTA4HALDH1A1MAPTHSD17B10CYP17A1 | |
| SCHEMBL9357255 | 0.71 | TAAR1 (0.56) | TAAR1LTA4HPNPMEN1KDM4A | |
| SCHEMBL28260270 | 0.70 | HTR2C (0.40) | TAAR1ALDH1A1MAPT | |
| SCHEMBL8001600 | 0.70 | — | — | |
| SCHEMBL11047959 | 0.70 | HSP90AB1 (0.47) | TAAR1LTA4HALDH1A1 | |
| SCHEMBL28216766 | 0.70 | ESR1 (0.48) | TAAR1 | |
| SCHEMBL6972732 | 0.70 | NOTUM (0.39) | TAAR1LTA4HALDH1A1NPC1 | |
| SCHEMBL3149298 | 0.70 | L3MBTL1 (0.49) | ALDH1A1MAPTL3MBTL1CYP17A1CYP11B1 | |
| SCHEMBL6971279 | 0.70 | HRH3 (0.38) | TAAR1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1370533-B1 | IMIDIAZOLE DERIVATIVES AND THEIR USE AS AGONISTS SELECTIVE AT ALPHA 2B OR 2B/2C ADRENERGIC RECEPTORS | ALLERGAN INC (US) | 2015-05-06 | — | — | EP | disclosed |
| WO-2013074320-A1 | ALPHA-2B RECEPTOR AGONIST AND ANTICONVULSANT COMPOSITIONS FOR TREATING CHRONIC PAIN | ALLERGAN, INC. (US) | 2013-05-23 | — | — | WO | disclosed |
| US-20120083508-A1 | ALPHA-2B RECEPTOR AGONIST AND ANTICONVULSANT COMPOSITIONS FOR TREATING CHRONIC PAIN | ALLERGAN, INC. (US) | 2012-04-05 | — | — | US | disclosed |
| US-20120083508-A1 | ALPHA-2B RECEPTOR AGONIST AND ANTICONVULSANT COMPOSITIONS FOR TREATING CHRONIC PAIN | ALLERGAN, INC. (US) | 2012-04-05 | — | — | US | disclosed |
| US-20100016355-A1 | ALPHA-2B ADRENERGIC RECEPTOR AGONIST AND SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITOR COMPOSITIONS FOR TREATING CHRONIC PAIN | GIL DANIEL W | 2010-01-21 | — | — | US | disclosed |
| US-20100016355-A1 | ALPHA-2B ADRENERGIC RECEPTOR AGONIST AND SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITOR COMPOSITIONS FOR TREATING CHRONIC PAIN | GIL DANIEL W | 2010-01-21 | — | — | US | disclosed |
| WO-2008079720-A1 | ALPHA-2B RECEPTOR AGONIST AND ANTICONVULSANT COMPOSITIONS FOR TREATNG CHRONIC PAIN | ALLERGAN, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008079728-A2 | ALPHA-2B ADRENERGIC RECEPTOR AGONIST AND SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITOR COMPOSITIONS FOR TREATING CHRONIC PAIN | ALLERGAN, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| US-20080153874-A1 | ALPHA-2B RECEPTOR AGONIST AND ANTICONVULSANT COMPOSITIONS FOR TREATING CHRONIC PAIN | ALLERGAN INC. | 2008-06-26 | — | — | US | disclosed |
| US-20080153874-A1 | ALPHA-2B RECEPTOR AGONIST AND ANTICONVULSANT COMPOSITIONS FOR TREATING CHRONIC PAIN | ALLERGAN INC. | 2008-06-26 | — | — | US | disclosed |
| EP-0954521-A1 | 4- (THIEN-3-YL)METHYL] IMIDAZOLE DERIVATIVES HAVING ALPHA2-ADRENOCEPTOR AGONISTIC ACTIVITY | Ortho-McNeil Pharmaceutical, Inc. (US) | 1999-11-10 | — | — | EP | disclosed |
| WO-1999051593-A1 | 4-THIONAPHTHYL-1H-IMIDAZOLES WITH ALPHA-2-ADRENERGIC ACTIVITY | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 1999-10-14 | — | — | WO | disclosed |
| EP-0889891-A1 | 4-[(THIEN-2-YL)METHYL]IMIDAZOLE DERIVATIVES HAVING ALPHA2-ADRENOCEPTOR AGONISTIC ACTIVITY | ORTHO PHARMACEUTICAL CORPORATION (US) | 1999-01-13 | — | — | EP | disclosed |
| US-5750720-A | ALPHA-ADRENORECEPTORS AND CENTRAL NERVOUS SYSTEMS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1998-05-12 | — | — | US | disclosed |
| US-5750720-A | ALPHA-ADRENORECEPTORS AND CENTRAL NERVOUS SYSTEMS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1998-05-12 | — | — | US | disclosed |
| US-5750720-A | ALPHA-ADRENORECEPTORS AND CENTRAL NERVOUS SYSTEMS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1998-05-12 | — | — | US | disclosed |
| WO-1997035857-A1 | 4-[(THIEN-2-YL)METHYL]IMIDAZOLE DERIVATIVES HAVING ALPHA2-ADRENOCEPTOR AGONISTIC ACTIVITY | ORTHO PHARMACEUTICAL CORPORATION (US) | 1997-10-02 | — | — | WO | disclosed |
| WO-1997035858-A1 | 4-[(THIEN-3-YL)METHYL] IMIDAZOLE DERIVATIVES HAVING α2-ADRENOCEPTOR AGONISTIC ACTIVITY | ORTHO PHARMACEUTICAL CORPORATION (US) | 1997-10-02 | — | — | WO | disclosed |
| WO-1997035858-A1 | 4-[(THIEN-3-YL)METHYL] IMIDAZOLE DERIVATIVES HAVING α2-ADRENOCEPTOR AGONISTIC ACTIVITY | ORTHO PHARMACEUTICAL CORPORATION (US) | 1997-10-02 | — | — | WO | disclosed |
| US-5621113-A | ALPHA 2 ADRENOCEPTOR AGONISTS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1997-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016355-A1 | ALPHA-2B ADRENERGIC RECEPTOR AGONIST AND SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITOR COMPOSITIONS FOR TREATING CHRONIC PAIN | ADRA2B, ADRA1B, ADRB1 | TAAR1 71/4885LTA4H 729/4885PNP 1541/4885 |
| US-20120083508-A1 | ALPHA-2B RECEPTOR AGONIST AND ANTICONVULSANT COMPOSITIONS FOR TREATING CHRONIC PAIN | CNR2, OPRL1, OPRD1 | TAAR1 531/4885LTA4H 379/4885PNP 2764/4885 |
| US-20080153874-A1 | ALPHA-2B RECEPTOR AGONIST AND ANTICONVULSANT COMPOSITIONS FOR TREATING CHRONIC PAIN | CNR2, OPRL1, OPRD1 | TAAR1 531/4885LTA4H 379/4885PNP 2764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.